Evotec stock holds just above 52-week low as guidance cut weighs

Evotec stock is trading only slightly above its 52-week low as investors digest a sharply reduced full-year guidance and lingering restructuring risks around Project Horizon and recent voting-rights changes.

Evotec (ISIN DE0005664809) stock is again trading close to its 52-week low, with the shares changing hands at around EUR 3.24 as of late August 2026, barely 0.9 percent above the EUR 3.19 floor set in July according to an Ad Hoc News market analysis dated September 1, 2026.

Stock hovers near yearly floor

According to a detailed Ad Hoc News review, Evotec shares recently traded at about EUR 3.24, only slightly above the 52-week low of EUR 3.19 from July 2026, highlighting how little buffer remains for investors at current levels.

The same analysis notes that Evotec’s market capitalization stands at roughly EUR 595 million as of late August 2026, a level that underscores how a relatively small change in ownership stakes can materially move percentage holdings.

Voting-rights notification adds ownership intrigue

On August 31, 2026, Evotec published a voting-rights notification under Article 40 of the German Securities Trading Act, revealing that a threshold was crossed on August 25, 2026; the company did not disclose which threshold or which shareholder was involved, but for a business valued at around EUR 595 million this type of stake change can be significant according to the Ad Hoc News coverage.

The same report points out that Evotec’s share price has fallen approximately 41 percent since the start of 2026, illustrating how the combination of operational setbacks, restructuring costs and revised guidance has steadily eroded equity value over the year.

Guidance cut and Project Horizon weigh on sentiment

Evotec’s share weakness is closely tied to its restructuring initiative dubbed Project Horizon, which is being financed through a convertible bond placement of EUR 116.1 million, as highlighted in the Ad Hoc News article on the company’s shareholder shifts.

Recent half-year figures released on August 13, 2026 showed that second-quarter group revenue fell 16.2 percent year on year to EUR 143.5 million, while first-half 2026 revenue declined to EUR 300.1 million compared with EUR 371.0 million in the same period of 2025, underscoring a significant slowdown in the company’s top line according to the same Ad Hoc News analysis.

Adjusted group EBITDA also deteriorated sharply: Evotec recorded approximately minus EUR 20.8 million in adjusted EBITDA for the second quarter of 2026 and minus EUR 42.7 million for the first six months of 2026, confirming that profitability is under clear pressure even before restructuring costs are fully absorbed.

Reflecting these trends, Evotec has cut its full-year 2026 guidance and now expects revenue between EUR 570 million and EUR 610 million alongside adjusted group EBITDA in a range of minus EUR 70 million to minus EUR 105 million, as reported consistently by Ad Hoc News and technology outlet IT Boltwise.

An IT Boltwise analysis emphasizes that despite ongoing cost-cutting measures, the revised EBITDA corridor still points to a materially negative result, underlining that the operational turnaround is progressing more slowly than many investors had hoped.

Since the publication of the half-year figures and guidance cut in mid-August 2026, Evotec’s share price has drifted about 2.4 percent lower, a muted but telling reaction that suggests the market had already priced in much of the bad news and now awaits concrete signs of improvement.

Analysts divided on outlook

The cautious tone in the market is reinforced by recent analyst actions: in mid-July 2026, research house TD Cowen downgraded Evotec from buy to hold and assigned a price target of USD 2.00, while HC Wainwright cut its target to USD 4.00 on the same day, according to the Ad Hoc News and IT Boltwise reports.

The wide gap between the USD 2.00 and USD 4.00 targets illustrates how divided the analyst community remains about Evotec’s future trajectory, with some expecting further downside risk while others still see recovery potential if Project Horizon delivers and guidance stabilizes.

Both analyst moves came shortly before the profit warning and guidance reset, effectively serving as early signals that the company’s earnings profile for 2026 would be weaker than previously anticipated.

Strategic partnerships yet to shift the valuation

To counterbalance the operational pressure, Evotec has pursued new strategic alliances, including a recently announced AI-driven research collaboration with Odyssey Therapeutics focusing on autoimmune and inflammatory diseases, as noted by Ad Hoc News and IT Boltwise.

However, roughly one month after this partnership was unveiled, Evotec’s share price had slipped by about 5.3 percent, indicating that investors view such scientific collaborations more as long-term portfolio options than immediate catalysts for earnings or cash flow.

The combination of a convertible bond-financed restructuring, shrinking revenue, negative adjusted EBITDA and a share price hovering just above its 52-week low means management has limited room for missteps; investors are likely to watch upcoming quarters closely for signs that the cost-saving program and partnership pipeline translate into tangible financial progress.

Drug discovery platform as long-term growth driver

Evotec is best known for its integrated drug discovery and development platform, which combines high-throughput screening, medicinal chemistry, translational biology and increasingly AI-supported approaches to help pharmaceutical partners identify and progress new therapeutic candidates.

The company generates revenue from discovery alliances, development milestones and potential royalty streams across a broad portfolio of partnered programs, many of which target areas such as oncology, metabolic disease and autoimmune indications.

While recent half-year 2026 figures show that short-term revenue and EBITDA are under pressure, Evotec’s diversified pipeline and platform-based business model are designed to deliver medium- to long-term growth as successful candidates move through clinical development and into commercialization with partners.

Evotec stock price and investor perspective

As of August 30, 2026, Evotec stock closed at EUR 3.37 on Xetra, approximately 5.5 percent above the 52-week low of EUR 3.19 and giving the company a market capitalization of about EUR 597.29 million according to an Ad Hoc News price snapshot; subsequent trading around EUR 3.24 to EUR 3.28 keeps the shares near that floor as of September 1, 2026.

Evotec SE stock facts

• Company: Evotec SE
• ISIN: DE0005664809
• WKN: 566480
• Ticker: EVT
• Trading venue: Xetra
• Price (as of August 30, 2026, 16:00): 3.37 EUR
• Market capitalization: 597.29 million EUR (as of August 30, 2026)
• Sector / Industry: Biotechnology, drug discovery
• Index membership: TecDAX